OCTREOETIDE

Reagent set to prepare 99m-Technetium-MIBI (Hexamibi) for diagnostic use. This preparation is administered intravenously after labeling with a sterile, non-pyrogenic solution of 99mTc-sodium pertechneciate. It is indicated to evaluate ischemic heart disease. The product allows to distinguish normal from abnormal myocardium, in addition to localizing the abnormality in patients with possible myocardial infarction, ischemic heart disease or coronary artery disorders. Evaluation of ischemic heart disease or coronary artery disease is accomplished through the use of rest and stress techniques. It is also useful in the evaluation of myocardial function using the first passage technique.

Presentation: Case with 5 kits (5 vials).
Each vial contains 0.5 mg hexamibi, exc. q.s.p. 24.6 mg, sterile lyophilized powder for injection.

Storage: between 2° and 8°C. Protect from light.
Unmarked Kit Shelf Life: 12 months.
Stability of the labeled kit: It is recommended to use the recently prepared radiopharmaceutical, before 6 hours of labeling.